These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 11351766)

  • 21. Acute coronary syndrome: are intervention and IIb/IIIa platelet inhibitors epiphenomena?
    Jackson G
    Int J Clin Pract; 2001; 55(6):351-2. PubMed ID: 11501219
    [No Abstract]   [Full Text] [Related]  

  • 22. Who needs Plavix? This super aspirin is meant mainly for people at high risk of having a heart attack or stroke.
    Harv Heart Lett; 2005 Mar; 15(7):6-7. PubMed ID: 15816078
    [No Abstract]   [Full Text] [Related]  

  • 23. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 24. Combination antiplatelet agents in ischemic cerebrovascular disease.
    Moussouttas M; Papamitsakis N
    Mt Sinai J Med; 2005 Jan; 72(1):16-22. PubMed ID: 15682258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Secondary prevention of cerebral ischemia. AMEVASC. Mexican Association of Cerebrovascular Disease].
    Barinagarrementeria F; Amaya L; Guzmán JL; Ibarra O; Loy Mdel C; Millán R; Neri G; Villarreal J; Araúz A; Cantú C
    Rev Invest Clin; 2002; 54(3):257-61. PubMed ID: 12183895
    [No Abstract]   [Full Text] [Related]  

  • 26. [Attack on many vascular fronts. Atherothrombosis trouble seldom comes alone].
    MMW Fortschr Med; 2004; 146 Suppl 1():4-5. PubMed ID: 15493408
    [No Abstract]   [Full Text] [Related]  

  • 27. Clopidogrel response variability, resistance, or both?
    Wiviott SD
    Am J Cardiol; 2006 Nov; 98(10A):18N-24N. PubMed ID: 17097413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Secondary prevention after ischemic stroke. High risk patients need special protection].
    MMW Fortschr Med; 2004; 146 Suppl 1():10-1. PubMed ID: 15493413
    [No Abstract]   [Full Text] [Related]  

  • 29. [Risk improves effectiveness. Proper administration of platelet aggregation inhibitors].
    Haberl R
    MMW Fortschr Med; 2002 Mar; 144(11):10. PubMed ID: 12066502
    [No Abstract]   [Full Text] [Related]  

  • 30. Antithrombotic treatment of NSTEMI/UAP. The interaction with PCI.
    Otterstad JE; Brosstad F
    Scand Cardiovasc J; 2004 Mar; 38(1):9-15. PubMed ID: 15204241
    [No Abstract]   [Full Text] [Related]  

  • 31. Clopidogrel for preventing cardiovascular events.
    Stulman J; McGinn T; Korenstein D
    Mt Sinai J Med; 2009 Apr; 76(2):194-7. PubMed ID: 19306382
    [No Abstract]   [Full Text] [Related]  

  • 32. Results of the management of atherothrombosis with clopidogrel in high-risk patients trial: implications for the neurologist.
    Fisher M
    Arch Neurol; 2006 Jan; 63(1):20-4. PubMed ID: 16401733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
    Wallentin L; Varenhorst C; James S; Erlinge D; Braun OO; Jakubowski JA; Sugidachi A; Winters KJ; Siegbahn A
    Eur Heart J; 2008 Jan; 29(1):21-30. PubMed ID: 18055486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
    Pongrácz E
    Clin Hemorheol Microcirc; 2004; 30(3-4):237-42. PubMed ID: 15258349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE.
    Mehta SR
    J Invasive Cardiol; 2003 Mar; 15 Suppl B():17B-20B; discussion 20B-21B. PubMed ID: 12724582
    [No Abstract]   [Full Text] [Related]  

  • 36. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38.
    Wiviott SD; Braunwald E; Murphy SA; Antman EM;
    Am J Cardiol; 2008 May; 101(9):1367-70. PubMed ID: 18435974
    [No Abstract]   [Full Text] [Related]  

  • 37. [Antiplatelet agents--problem for cardiac surgeon].
    Bochenek A; Wilczyński M
    Kardiol Pol; 2006 Nov; 64(11):1329-31. PubMed ID: 17165174
    [No Abstract]   [Full Text] [Related]  

  • 38. Excess rates of nonfatal myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel (preventing clinical events or chasing enzymatic ghosts?).
    Serebruany VL
    Am J Cardiol; 2008 May; 101(9):1364-6. PubMed ID: 18435973
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term management of patients with unstable angina and non-ST-elevation MI.
    Banas JS
    J Fam Pract; 2004 Jun; 53(6):451-5. PubMed ID: 15189718
    [No Abstract]   [Full Text] [Related]  

  • 40. Plavix reduces death risk following a heart attack.
    Health News; 2005 Jun; 11(6):4. PubMed ID: 16127791
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.